Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Doing research. Trying to find out why SAVA almost doubled in the last month. Was that run up before the announcement?
Who are the companies that are also attempting to regenerate synapses that Dr. Alkon is referring to in the video?
Is Athira looking like a good flip?
Urge2surge you remind me of someone.??
As prevalent as AD is, you would think getting 100 qualified patients would be easy.
Can I start a rumor of a “leak”??
Wow…..what wild swings!
“ Per my conversation with the company, the goal is to have a readout in H1 ’22.” I don’t think it was a misunderstanding. The author made a point to let us know that he got this straight from the company. I'm sure he double checked it with them. Also, Alkon has mentioned a possible trial ending in Q2.
Thanks Cyosol,
With all the selling volume lately I would think a lot of shares are being transferred from the investors to the investment funds, which is a good thing. Spread some of those millions of shares out to investment funds will make for a more stable stock. Less concentration is good.
Cyosol, can you explain how the expiration date of the warrants would keep a lid on the stock price? Couldn’t the demand for shares eat up the selling supply, pushing the price higher?
Do you think the buying will exhaust the selling allowing the price to rise?
Who’s doing the buying and selling during the recent increase in volume? I guess, the investors are doing the selling and investment funds are do the majority of the buying.
Thanks. I knew that, but I allowed the wording of the press release to confuse me. Please, hurry bryostatin! :)
Thanks Cyosol,
Confusing. They stated a “unit” is composed of one share and one warrant. And, the combined price of a unit was $7.547 with the warrant portion at $8.51. I calculated that that would leave a share price of $6.58.
If my math is correct the funding was at a price of $6.58. Correct?
Yeah, if they are exercised. I meant dilution to make it to the end of the trial.
Are you factoring in future dilution into your numbers?
It’s hard to compare trials that measure results with SIB with those measured with ADAS-Cog.
I am allowing myself to think big here. If results of current trial produces a 10 point spread between drug and placebo, what would be a fair market cap target or range for this company? With this second cycle of drug, you never know.
The company said estimated end of trial is Q2 or Q3 of 2022. Correct? A friend said she never heard Q2.
Thanks Coach, for your response. Just wondering, if in that first trial the handful of patients that were on no drugs at all strongly contributed to that 94% results. Testing only on drug-naive patients would have been interesting.
In the previous trial, were there a difference in the results in the patients who had previously been on memantine vs those who had never been on memantine?
Does it seem that the reduced number of outstanding shares after a reverse split makes it more likely than normal for the company to sell additional shares?
The company stated. “ The availability of increased drug supply will also enable us to look to commence additional informative trials to supplement the data we expect to generate from our NIH supported Phase 2 trial in moderate to severe Alzheimer's Disease."
Does this mean they are planning of holding smaller, shorter trials that will be produced before the end of the current A.D. trial?
I'm buying for the trade. I think the big investors will do what it takes to get the stock price over $4.
Runncoach are you thinking the uplisting to the Nasdaq will create upward pressure or downward pressure on the stock?
Runncoach, you mentioned that the moderately severe patients improved at all check points in the previous trial. I'll trying to go back and find that breakdown. Can you elaborate on the data?
As always, thanks for the information guys.
Does this trial allow peeking at results before the end of the trial?
I hope that it doesn’t take years of treatment with bryostatin in humans to have an effect (in human years).
Thanks for the reply Cyosol. I've been focused on the non-supplement things I could do. Now I want to begin to take supplements, especially nootropics. There’s so many options.
I think I might give this a try, and add an antioxidant. I'm also in my 50's and it's pass the time that I start implementing cognitive decline mitigating strategies.
Are you guys taking anything for brain health? Just curious.
I bought a couple hundred shares because I think the price will continue to rise over the coming months. The price seems cheap right now. In the meantime I will look into that ALS issue. I'm still keeping my SNPX shares though.
Seeking Alpha article on AB Science.
https://seekingalpha.com/article/4396206-ab-sciences-masitinib-uncertain-success-for-alzheimers-disease?utm_medium=email&utm_source=seeking_alpha&mail_subject=lane-simonian-ab-science-s-masitinib-an-uncertain-success-for-alzheimer-s-disease&utm_campaign=rta-author-article&utm_content=link-0
Synaptogenix has the most upside, but do anyone own any shares of AB Science or Athira?
I'm still trying to get up to speed. Thanks Runncoach and others for your help.
I am calculating that the company currently has about 5.6 million shares of warrants and options. Am I correct?
I'm guessing that at the end of this trial, the company will have a total of 20 to 25 million shares including warrants. And with very good results, a market cap of multi-billion dollars because of the current lack of treatments for A.D. Or, am I off on the potential value? Can you list any other companies with promising A.D. trial results whose market value I can study?
Thanks for the reply Coach. I'm trying to get a guesstimate of about how many fully diluted shares the company will have two years from now.
It is almost certain that the company will need to raise money at some point. Question: How much do you think they will raise?